Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of phenylimidazoles and azoles. It has been assigned DrugBank ID DB07125 and is also known by the code names PD006082 and 4RB. The molecule features an imidazo[1,2-b]pyridazine core substituted with a benzoic acid moiety. There are no approved medical indications or clinical trials reported for this compound as of now. Its mechanism of action and biological targets have not been described in public databases or literature sources available as of June 2025. The compound appears to be experimental with no evidence of development for any specific disease or therapeutic area.[1][9][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid.